Kelonia Therapeutics
ASH 2025: Breakthroughs in In Vivo CAR-T Data from Kelonia; Phase 3 Wins for Lilly, J&J, and Novartis
ASH 2025; in vivo CAR-T; Kelonia Therapeutics; KLN-1010; multiple myeloma; Johnson & Johnson; Lilly; Novartis; CAR-T therapy; Phase 3 trials